Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for the news.
I have an email to David Hale in and will let you know what I find out.
I heard back from IR. This s the response.
The CVRs were created as part of the Metabasis acquisition in 2008 and shareholders of Metabasis were given the CVRs along with other consideration just in case some of the assets in Metabasis generated value in the future. Some have worked out and paid out some value, others have not paid any value.
There is a shareholder rep from Metabasis that is responsible for looking after the CVR holders. His name is David Hale and here is his email. dfhale@biopharmaventures.com
There are four CVRs that came from the Metabasis transaction. They trade publicly. Here is the list with a tidbit of info about each:
TRBeta CVR is ticker LGNZZ. This is related to the TRBeta programs at our partner Viking
Glucagon CVR is ticker LGNXZ. This is related to the GRA program at our partner Metavant
General CVR is ticker LGNYZ. A catch all for another couple assets.
Roche CVR is ticker LGNDZ . This is related to a collaboration that Roche had with Metabasis related to HCV compounds. The collaboration has been terminated.
Lastly, there is a CVR agreement that governs the terms of the CVRs and it can be found on the SEC website. Link is here:
https://www.sec.gov/Archives/edgar/data/886163/000119312509215910/0001193125-09-215910-index.html
Patrick O'Brien
SVP Investor Relations
Ligand Pharmaceuticals, Inc.
3911 Sorrento Valley Boulevard, Suite 110
San Diego, CA 92121
O: (858) 550-7768
M: (650) 393-0030
In the news everyday.
https://apple.news/A1NskTlcBTlORap0fP9VxHA
Pharmaceutical companies continue to make headlines as governments and investors hang their hopes on a steady recovery from the Covid-19 pandemic. Gilead Sciences CEO Daniel O'Day said Sunday the company would be donating its entire supply of remdesivir to treat coronavirus patients. Roche Chairman Christoph Franz said the drugmaker will invest more than $437 million in a German testing site. Another week of quarterly reports lies ahead, and more retail locations are reopening as U.S. states loosen lockdown restrictions.
I have been unable to find it as well, but lgndz seems to react better to Gilead news.
I am researching that now. I will post when I find that.
They are not companies. They are cvr’s. They pay out when the company lgnd reaches certain milestones.
From 2015. These things pay divy’s.
https://www.sec.gov/Archives/edgar/data/886163/000119312515210721/d935358d8k.htm
link please, thx
Biotech company Gilead Sciences (GILD) is trying to corral Covid-19 with an experimental coronavirus treatment — an effort that has stoked renewed hopes for GILD stock.
The biotech company is advancing a former Ebola virus treatment, remdesivir, in clinical studies of patients with Covid-19, the disease caused by a new form of coronavirus discovered last year. But shares of GILD stock have been volatile amid its coronavirus treatment efforts.
Gilead is also trying to stake its claim in HIV treatments. It's facing off against an outlet mostly owned by GlaxoSmithKline (GSK) called ViiV Healthcare. Biotech company Gilead is also pushing into cancer drugs after wrapping its takeover of Forty Seven.
All in all, should investors consider buying GILD stock right now?
A Fundamental Look At GILD Stock
Gilead used to be a powerhouse in treating hepatitis C.
The drug called Sovaldi gained Food and Drug Administration approval in 2013. The following year, it raked in $10.3 billion in sales. Gilead also had success with drugs dubbed Harvoni and Epclusa. About 95% of hepatitis C patients can now be cured with treatment.
In 2016, sales in Gilead's formerly bullish hepatitis C unit tumbled 23% as the number of cures increased. That trend has continued ever since despite the addition of a new hepatitis C drug known as Vosevi.
In the wake of that hepatitis C drug sales cliff, earnings have painted a dim picture. Adjusted earnings per share have declined for 14 of the past 15 quarters. In the fourth quarter, adjusted Gilead income fell 10% to $1.30 per share. That widely missed estimates for $1.58 a share.
Sales inched up 1% to $5.88 billion. That topped expectations for $5.73 billion. But it also extended a recent trend of flat or single-digit percentage increases in sales growth. As a result, GILD stock dipped on Feb. 5, the day following its fourth-quarter earnings report.
Analysts polled by Zacks Investment Research expect these trends to continue in the first quarter. On average, they expect adjusted Gilead earnings of $1.37 per share on $5.37 billion in sales. Earnings would slide 22.2% and sales would rise 1.6%.
Looking For Better Growth
This volatile trend doesn't put GILD stock in line with CAN SLIM rules for investing. Growth stock investors should look for stocks with 20%-25% or better earnings growth in the most recent quarter.
Notably, Gilead's after-tax margin slid in the fourth quarter to 28.1%. The biotech company's after-tax margin has now decelerated for five of the past six quarters. Strong stocks show a trend of margin acceleration.
Gilead's fourth-quarter after-tax margin lagged fellow large-cap biotech company Amgen (AMGN), which had a margin of 35.1%. Still, Amgen's margins have decelerated for two straight quarters. But top-rated biotech Vertex Pharmaceuticals (VRTX) was in the middle with a margin of 31.4%.
Vertex stock has a perfect Composite Rating of 99, meaning it ranks in the top 1% of all stocks in terms of key growth metrics. GILD stock has a Composite Rating of 90. The CR is a 1-99 measure of a stock's key growth metrics, with 99 the best.
Annual Metrics: What Does 2019 Tell Us?
In 2019, Gilead earnings were $6.63 per share, minus certain items. That edged down a fraction on a year-over-year basis. Operating cash flow came out to $6.69 per share — less than 1% ahead of profit. The fastest-growing companies have operating cash flow at least 20% above earnings per share.
But sales inched up 1% to $22.45 billion. That was the first time sales rose since 2015.
Less bullishly, Gilead's annual pretax margin hit 47.6% — its lowest in six years. Pretax margin also slowed for the fourth year running. When looking for strong stocks, it's smart to consider those with accelerating pretax margins.
In 2020, analysts expect Gilead to earn $6.42 per share on $22.34 billion in sales. Earnings would slide 3.2% and sales would dip a fraction.
GILD Stock Technical Analysis: No Chart Pattern
Shares of GILD stock aren't currently forming a definite chart pattern.
As of midday trading on April 20, GILD stock was above both its 50-day moving average and 200-day line. Gilead's relative strength line has mostly declined since 2014 — meaning it has lagged the S&P 500 during that period. But that trend appears to be reversing now.
Gilead has an RS Rating of 96, putting its 12-month performance in the top 4% of all stocks. Leading stocks tend to have RS Ratings of 80 or above.
Gilead stock ranks No. 27 out of nearly 600 publicly traded biotech stocks by Composite Rating in IBD's Stock Checkup. Keep tabs on those scores by visiting IBD Digital.
Which Mutual Funds Are Investing In Gilead?
Fidelity Contrafund remains a long-term key investor in GILD stock. The largest actively managed mutual fund in the world increased its holding in GILD stock in December and March.
Further, more funds are either adding GILD stock or increasing their positions than cutting their holdings, as of late March. Several of those adding funds have A ratings.
GILD Stock News: Coronavirus Treatment In Testing
Earlier this month, Gilead said it's creating a stockpile of experimental coronavirus treatment, remdesivir. The biotech company plans to have more than 500,000 courses of remdesivir by October and more than 1 million by year's end.
Further, Gilead says it plans to donate its existing supply of remdesivir for compassionate use, expanded access or clinical studies. Results from compassionate-use of the drug have been promising as well. These programs allow access to a drug for patients who can't enroll in a study.
In early April, Gilead said 53 patients who received remdesivir under compassionate-use programs showed a clinical improvement of 84% after 28 days of follow-up. Across all patients, 68% showed improvement in oxygen support class over a median follow-up of 18 days.
The European Medicines Agency recommended compassionate use of remdesivir based on laboratory tests. Although remdesivir isn't approved anywhere, this will allow patients in some European countries to access the experimental coronavirus treatment in serious cases.
Will GILD Stock Fly On Coronavirus Treatment?
In mid-March, Gilead said it had become swamped with compassionate-use requests for remdesivir in U.S. patients with Covid-19. So, the biotech company suspended that program and, instead, put together an expanded-use program.
Further, Chief Executive Daniel O'Day said in late March the biotech company expects to have initial results from clinical tests of its coronavirus treatment within "the coming weeks."
On March 13, GILD stock popped on the test results for its coronavirus treatment in patients sickened on the Diamond Princess cruise ship in Japan. A total of 17 passengers received intravenous remdesivir once a day for 10 days to treat it.
By the end of the test, all were still alive and more than half recovered. That sent GILD stock up 3.2%.
Earlier in the month, analysts suggested the biotech company could have the results of studies of its coronavirus treatment in March or April. The suggestions prodded GILD stock to pop 1.9% and 5.4% on two separate days. In fact, GILD stock hit a two-year high on March 6.
Shares also popped on March 2 after the biotech company announced its $4.9 billion plan to buy Forty Seven, a cancer-focused player. Forty Seven is currently testing an immuno-oncology drug in blood cancers and solid tumors.
Acquisitions Bolster Gilead's Pipeline
The addition of Forty Seven wrapped on April 7, and helps bolster Gilead's pipeline of oncology drugs. In 2017, Gilead spent $11.9 billion to acquire Kite Pharma, the maker of Yescarta, a CAR-T drug. CAR-T drugs also target cancer by training the immune system.
In late February, GILD stock rose nearly 5% after a World Health Organization representative said the biotech company's experimental coronavirus treatment, remdesivir, might be the best candidate for treating Covid-19.
Also that day, documents showed China's National Medical Products Administration had accepted the application for Yescarta, in treating a form of blood cancer known as large B-cell lymphoma. The application was filed by a joint venture known as Fosun Kite Biotechnology.
In early February, GILD stock rose 5% in a single day after the biotech company said it would send remdesivir to China to test it as a coronavirus treatment. The drug previously showed promise in a 35-year-old U.S. patient with a new form of coronavirus.
Biotech Company Announces Partnerships
The FDA granted a Gilead drug a speedier priority review in the treatment of mantle cell lymphoma, a type of blood cancer. That drug, KTE-X19, is being developed by Gilead's Kite.
In December, Gilead and Japan-based pharma Eisai entered into a collaboration agreement for the co-promotion of a drug called filgotinib as a rheumatoid arthritis treatment, pending approval. Gilead announced it submitted an application for filgotinib approval to U.S. regulators.
The biotech company also announced China approved chronic hepatitis C treatment Vosevi.
In November, Gilead said a pooled analysis showed strong results for filgotinib in rheumatoid arthritis treatment. Filgotinib is being developed with Galapagos (GLPG). The two companies announced a collaboration deal in August 2019.
Under terms of that deal, Gilead paid Galapagos $3.95 billion up front. Gilead also made a $1.1 billion equity investment in the other biotech company. The deal was initially announced July 14, 2019. Gilead will have access to six drugs in clinical studies and 20 preclinical medicines.
Other Gilead Stock News
Early last year, Gilead said its nonalcoholic steatohepatitis drug, selonsertib, failed to improve fibrosis — a key goal of the studies. Gilead tested selonsertib in patients with stage 3-4 fibrosis. Fibrosis is a type of liver damage. Stage 4 is the worst level.
Meanwhile, rival Intercept Pharmaceuticals (ICPT) said its potential nonalcoholic steatohepatitis drug, Ocaliva, hit its key goal in a study. Ocaliva improved damage in patients with stage 3 fibrosis.
But Gilead isn't backing down. In April 2019, Gilead announced a collaboration with privately held Insitro to investigate potential treatments for nonalcoholic steatohepatitis. Insitro uses machine learning to build models to understand diseases.
Importantly, Gilead named a new chief executive in December 2018. Former Roche (RHHBY) executive Daniel O'Day took the helm at Gilead on March 1, 2019, replacing former Gilead CEO John Milligan.
So, Is Gilead Stock A Buy?
Based on CAN SLIM investing principles, the short answer is no. Gilead stock is not a buy right now based on the metrics that other big winning stocks showed at the beginning of major price runs.
Investors should look for stocks that beat expectations while growing sales and earnings.
Further, Gilead stock isn't currently forming a definitive chart pattern. It's best to buy stocks that have recently surpassed a buy point and are within the 5% chase zone. (Related: See other stocks near a buy zone.)
Gilead also looks poised to report declining earnings and sales growth in the first quarter. But the sales growth forecast is not be stout enough to fall in line with CAN SLIM rules of investing. It will be key to watch Gilead's efforts to advance a coronavirus treatment in the coming months.
ImmunoPrecise Provides Updates on B Cell Select™ and Deep Display™ Programs for SARS-CoV-2 Antibody Discovery
BY PR Newswire
— 8:00 AM ET 04/17/2020
We caution that this news release is not making any express or implied claims that we have the ability to eliminate the SARS-CoV-2 virus at this time. We further caution that we have not undertaken any clinical trials.
VICTORIA, April 17, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. ( IPATF
Loading...
Loading...
) (the "Company" or "IPA") (OTC QB: IPATF) is pleased to provide an update on its research activities for the novel coronavirus (SARS-CoV-2) which outlines the Company's workflows for their experimental vaccines and therapeutics for the research community.
IPA's multitargeting approach combines various SARS-CoV-2 spike protein forms with the Company's diverse technologies. Hence, IPA anticipates that it can accelerate anti-SARS-CoV-2 human antibody discovery, targeting multiple viral epitopes and mechanisms of viral evasion, by immunizing Ligand's OmniRat® animals using the Company's Rapid Prime™ protocol followed by IPA's B cell Select™ and hybridoma generation in parallel with human, naive phage library screening. Subsequent high-throughput binding assays, computational Artemis™ optimization, and protein interaction analyses permit faster preclinical lead selection.
"In addition to using our antibody discovery platforms for the potentially rapid identification of a diverse panel of fully SARS-CoV-2-specific antibodies, we aim targeting additional novel epitopes which are likely inaccessible to conventional antibody formats by screening our in-house, highly complex, VHH repertoire (collection of variable regions of heavy chain antibodies, a region which binds to the target immunogen)," stated Ilse Roodink, Chairwoman of Talem's Scientific Advisory Committee and Coronavirus Global Project Leader. "Due to the relative high sequence homology of VHHs with human antibodies, extensive humanization is not required and therefore, our discovery strategy mixture will significantly contribute to the fast generation of a monoclonal antibody cocktail with broad epitope coverage and diverse functionalities, which is key to successful development of an effective, long-lasting therapy with a high safety profile."
Apart from the various SARS-CoV-2 spike protein forms which IPA has been producing for use in the therapeutic development, data obtained during the discovery and characterization of lead antibody candidates may be of significant value in the reverse-engineering of vaccine candidates used in the formulation of an effective, but low-risk, vaccine.
Jennifer Bath, Ph. D., has reviewed and approved the scientific disclosure contained in this news release.
About ImmunoPrecise Antibodies Ltd. ( IPATF
Loading...
Loading...
)
ImmunoPrecise is a full-service, therapeutic antibody discovery Contract Research Organization offering species agnostic, multi-format, characterized and engineered, human monoclonal antibodies, on an abbreviated timeframe, for its pharmaceutical clients. For further information, visit www.immunoprecise.com or contact solutions@immunoprecise.com. There is no assurance that ImmunoPrecise will be successful in the development of a vaccine and/or therapeutic against the new coronavirus.
Agreed. Faster money as well. Imagine if that would also work with Bees.
Sun Kissed to Acquire Leading Digital Marketing and Monetization Platform Led By Industry Star
NEW YORK, April 9, 2020 – Sun Kissed Industries Inc. (OTCMKTS:SKDI) (“Sun Kissed”, “SKDI”, or the
“Company”), an emerging leader in the CBD Food and Beverage marketplace, and NuMuni Inc.
(“NuMuni”), a monetization platform developed for digital media publishers, software providers, and online
games (together, the “Parties”), are excited to announce the signing of a Letter of Intent (the “LOI”)
whereby Sun Kissed will acquire one hundred percent ownership of NuMuni https://numuni.io .
Management notes that Robert Reynolds, the founder and CEO of NuMuni, is a top innovator in the
advertising based virtual currency monetization industry, which has grown to generate billions of dollars
per year. Reynolds’ prior endeavor, CPALead, was the 40th fastest growing private company in the US,
eventually becoming the largest incentive-based advertising marketplace in the world, serving ads to over
one billion people worldwide and generating over $100 million in sales.
“Robert is a visionary at the cutting-edge in the fintech and digital marketing space and we believe
NuMuni will be a game-changing piece of the puzzle for Sun Kissed. Our strategy is to build a company
around talented individuals with game changing assets. We started with Ilan Freeman from Hakuna who
is an award winning CEO and now we add to that Robert Reynolds. With their sage advice, we will
continue to aggressively chase down the joint venture and acquisition opportunities that the current
economic climate has offered up to us ” noted Carl Grant, CEO of Sun Kissed.
Numuni is a powerful monetization platform developed for digital media publishers, software providers,
and online games. It enables the privacy-friendly monetization of users’ spare computer processing
power, incentivizing participation through premium digital media content distribution. NuMuni is a
revolutionary solution to the increasing impotence of traditional digital advertising strategies. Freed
resources are pooled to form a distributed supercomputer that can mine cryptocurrency, run scientific
simulations, train AIs, perform 3D rendering, and undertake many more tasks.
Sun Kissed also recently completed the acquisition of Products Group Inc, DBA/ Hakuna (“Hakuna”), a
leading CBD-based products company with a nationwide distribution footprint spanning more than 20 US
states. Management strongly believes the acquisition of NuMuni will present enormous synergies with its
Hakuna strategy given the critical role that online and retail marketing will play in developing the value of
the Hakuna brand in the quarters ahead.
About Sun Kissed Industries, Inc.
Sun Kissed Industries Inc. (OTCMKTS:SKDI) is an emerging leader in the CBD-based products
marketplace. The Company is pursuing meaningful acquisitions as part of an aggressive M&A strategy
designed to position Sun Kissed as a dominant player in a well-defined, high-growth niche within the
rapidly expanding CBD sector.
FORWARD-LOOKING STATEMENTS:
Robert Reynolds
Hakuna CEO, Ilan Freeman commented, “Robert Reynolds is a rock star, and the machine he has built in
NuMuni is going to make our job a lot easier. I’m extremely pleased to bring NuMuni into the equation and
The more important question is when is the next milestone for the next dividend?
In the 8k
Item 2.02 Results of Operations and Financial Condition.
On April 6, 2020, Ligand Pharmaceuticals Incorporated (the “Company”) disclosed that its estimated cash and cash equivalents were approximately $735 million and the outstanding principal amount of its 0.75% convertible senior notes due 2023 (the “2023 Notes”) was approximately $516 million, in each case, as of March 31, 2020. These amounts are unaudited and preliminary, and are subject to completion of financial closing procedures. As a result, these amounts may differ from the amounts that will be reflected in Ligand’s financial statements as of and for the quarter ended March 31, 2020.
The information in this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such a filing.
Item 8.01 Other Events.
On April 6, 2020, the Company announced that it had repurchased approximately $234.4 million in principal of the 2023 Notes for approximately $203.8 million in cash, including accrued interest of $0.6 million, during the quarter ended March 31, 2020. After the repurchases, approximately $516 million in principal amount of the 2023 Notes remain outstanding. The Company may continue to use cash on hand to repurchase additional 2023 Notes through open-market transactions, including by entering into a Rule 10b5-1 trading plan to facilitate open-market repurchases, or otherwise, from time to time. The timing and amount of repurchase transactions will be determined by the Company’s management based on its evaluation of market conditions, trading price of the 2023 Notes, legal requirements and other factors.
In connection with the repurchases of 2023 Notes repurchased during the quarter ended March 31, 2020, the Company expects to enter into amendments to the bond hedge transaction confirmations entered into in connection with the issuance of the 2023 Notes to provide for the options thereunder corresponding to such repurchased 2023 Notes to remain outstanding notwithstanding such repurchase.
The Company also announced on April 6, 2020, that it had repurchased approximately 473,000 shares of its common stock for approximately $37 million pursuant to its previously announced $500 million stock repurchase program. As of March 31, 2020, the authorized amount remaining under the share repurchase program was approximately $253.5 million.
Working to Supply Remdesivir for COVID-19
Since the moment the novel coronavirus that causes COVID-19 was identified, Gilead has mobilized every area of our organization to respond to the global health emergency. We are harnessing our decades of expertise in antiviral research and development, including more than 10 years of work on remdesivir specifically [click here to learn more], to advance a potential treatment for COVID-19 and help meet the ever-growing patient needs, should the medicine receive emergency authorizations or regulatory approvals.
Remdesivir is an investigational agent. It is not approved anywhere globally and has not been demonstrated to be safe or effective for any use. In anticipation of potential future needs, we have accelerated manufacturing timelines to increase our available supply as rapidly as possible. We are doing this before knowing whether remdesivir will be determined to be safe and effective to treat patients with COVID-19.
Manufacturing Process
Since January, Gilead has invested significant capital to establish a supply chain capable of large-scale production of remdesivir.
The production of remdesivir is a long, linear chemical synthesis process that must be completed sequentially and includes several specialized chemistry steps and novel substances with limited global availability. The process is both resource- and time-intensive, with some individual manufacturing steps taking weeks to complete. Because remdesivir is administered intravenously, production also requires sterile drug product manufacturing capabilities, which limits the number of organizations capable of manufacturing the medicine. This complex process impacts the ability to rapidly produce large quantities of drug supply in an emergency situation like the COVID-19 pandemic. In light of these realities, Gilead worked early on, before any clinical trials had started, to procure a steady flow of long-lead-time raw materials that will accelerate large-scale production of remdesivir by our current and future partners once these materials become available in significant quantities.
Over the last several weeks, we have also worked to shorten the manufacturing timeline through process improvements. The typical timeline for manufacturing a drug like remdesivir at scale is nine to 12 months; we have reduced that period to six to eight months. We continue to work on optimizing the chemical synthesis processes to further accelerate product deliveries and volumes.
Current and Projected Supply
As of January 2020, we were not actively manufacturing remdesivir. The manufacturing supply chain was scaled to periodically make small amounts of product for a compound in early development. We had inventory of finished product to treat just 5,000 patients.
Since then, we have proactively and rapidly scaled our supply chain. As of late March, using the active ingredient we already had in our inventory, we have increased our supply to more than 30,000 patient courses of remdesivir on hand, assuming a 10-day course of treatment for patients. As new raw materials arrive over the next few weeks from manufacturing partners around the world, our available supply will begin to rapidly increase.
Every day we are improving processes, shortening timelines and increasing volumes as we work to bring remdesivir to patients as soon as possible. Our goal is to produce a total of:
More than 140,000 treatment courses by the end of May 2020
More than 500,000 treatment courses by October 2020
More than 1 million treatment courses by December 2020
Several million treatment courses in 2021, if required
Capacity Expansion through External Manufacturing
We have supplemented our internal manufacturing with significant additional capacity from multiple manufacturing partners in North America, Europe and Asia. Through these efforts, we believe we have created a manufacturing network capable of producing large volumes of remdesivir at the fastest pace feasible. Looking ahead, we are building a geographically diverse consortium of pharmaceutical and chemical manufacturing companies to help us meet and exceed these production goals by expanding capacity for raw materials and production beyond what any company could do individually.
Efforts to Further Increase Supply
While cases of COVID-19 continue to increase, only a portion of patients experience severe symptoms that may make them appropriate candidates for treatment with remdesivir. Patients currently receiving remdesivir through clinical trials or expanded access are hospitalized and have moderate to severe manifestations of COVID-19, such as early respiratory failure. According to the World Health Organization, approximately 14% of patients with COVID-19 will experience severe manifestations of the disease that require hospitalization and supplemental oxygen, and 5% will require treatment in intensive care units. The potential benefits and risks of treatment with remdesivir for COVID-19 are not yet known.
Gilead is also studying a five-day course of treatment for COVID-19 in ongoing clinical studies. If a five-day dosing duration is shown to be safe and effective, this would increase the number of patients who could be treated with the current supply projections. Our researchers are also looking at the future potential for developing inhaled and potentially oral dosage forms of remdesivir to help alleviate the need for hospital administration of the drug.
We are doing everything we can to accelerate manufacturing timelines and quantities of remdesivir to meet the growing demand for emergency use of the medicine from around the world and for clinical trials to determine whether remdesivir is safe and effective for the treatment of COVID-19. In addition to multiple ongoing clinical studies actively enrolling patients, we are implementing expanded access programs as quickly as possible to help the most critically ill patients around the world with our limited supply.
https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-sciences-and-second-genome-announce-strategic-collaboration-in-biomarker-and-inflammatory-bowel-disease-drug-discovery
Can you please tell me the strike price and terms of LGNYZ. ?
Current and Projected Supply
As of January 2020, we were not actively manufacturing remdesivir. The manufacturing supply chain was scaled to periodically make small amounts of product for a compound in early development. We had inventory of finished product to treat just 5,000 patients.
Since then, we have proactively and rapidly scaled our supply chain. As of late March, using the active ingredient we already had in our inventory, we have increased our supply to more than 30,000 patient courses of remdesivir on hand, assuming a 10-day course of treatment for patients. As new raw materials arrive over the next few weeks from manufacturing partners around the world, our available supply will begin to rapidly increase.
Every day we are improving processes, shortening timelines and increasing volumes as we work to bring remdesivir to patients as soon as possible. Our goal is to produce a total of:
More than 140,000 treatment courses by the end of May 2020
More than 500,000 treatment courses by October 2020
More than 1 million treatment courses by December 2020
Several million treatment courses in 2021, if required
Capacity Expansion through External Manufacturing
We have supplemented our internal manufacturing with significant additional capacity from multiple manufacturing partners in North America, Europe and Asia. Through these efforts, we believe we have created a manufacturing network capable of producing large volumes of remdesivir at the fastest pace feasible. Looking ahead, we are building a geographically diverse consortium of pharmaceutical and chemical manufacturing companies to help us meet and exceed these production goals by expanding capacity for raw materials and production beyond what any company could do individually.
https://www.gilead.com/purpose/advancing-global-health/covid-19/working-to-supply-remdesivir-for-covid-19
What do you think we will be worth if LGND stock price is worth 314?
So LGNDZ has a strike price of $315 and change in order to be converted for a one for one share of LGND with about a two year window. What are the details of the LGNYZ CRV? Does anyone know?
Insiders buying.
I believe this is why it went up.
Not only is the right thing to do , but it indicates Kim thinks we are at the cusp and doesn’t want to lose the team.
My company dropped us like a rock, and they can afford the bridge. I can only imagine that it will bight them in the ass in the long run. It is going to cost them more to hire and train ,than it would of to carry us for a month. Instead they pushed us onto the unemployment system.
Another Tweet
2019 EOY Disclosure published. It's the last report before we show Hakuna revenue. (Will be in Q1 2020 report).
Main point of interest is we have now reduced our debt (through zero-consideration forgiveness).
We 'retired' around $300k Q4 2019.
backend.otcmarkets.com/otcapi/company…
#skdi